KLK3 and pachyonychia congenita: Advanced PC, including metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-naïve prostate cancer (mCNPC), is characterized by rising prostate-specific antigen (PSA) levels—indicating a significant risk for the development of disease progression and PC-specific death [6].